AYTU Insider Grant — CCO Awarded 12,500 Restricted Shares

Rhea-AI Filing Summary

Officer grant and ownership change: The Chief Commercial Officer received a grant of 12,500 restricted shares of common stock that vest over time, increasing his beneficial ownership to 36,102 shares. The award was issued at a price of $0, indicating a stock-based compensation grant rather than a cash purchase. One-third of the restricted shares vest on 10/03/2026, with the remaining shares vesting in eight equal quarterly installments beginning 01/03/2027.

This transaction is a non-derivative, officer-level compensation event that aligns the officer's interests with shareholders through time-based vesting. The restricted nature of the shares means transfer or sale will be limited until vesting occurs.

Positive

• 12,500 restricted shares granted to the Chief Commercial Officer, increasing alignment with shareholders
• Vesting schedule includes a meaningful cliff: 1/3 vests on 10/03/2026, then structured quarterly vesting

Negative

• Grant issued at $0 (compensation expense) which will be recorded when recognized
• Additional shares become available on vesting, increasing potential dilution to existing holders

Insights

Compensation & Governance Analyst

Time‑based restricted stock aligns CCO incentives with long-term share performance.

The grant of 12,500 restricted shares to the Chief Commercial Officer increases his direct holdings to 36,102 and is structured with a clear vesting schedule: one‑third on 10/03/2026 and the remainder in eight equal quarterly installments starting 01/03/2027.

This design ties realized value to tenure and market performance while delaying full dilution until vesting dates. Monitor forthcoming periodic filings for recognition of compensation expense and any updates if vesting conditions change within the next 12–18 months.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PYSZCZYMUKA GREG

(Last) (First) (Middle)

C/O AYTU BIOPHARMA, INC.

7900 EAST UNION AVENUE, SUITE 920

(Street)

DENVER CO 80237

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AYTU BIOPHARMA, INC [ AYTU ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/03/2025		A		12,500(1)	A	$0	36,102	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Grant of restricted stock, which vest as follows: 1/3 on October 3, 2026, with the remaining restricted stock vesting in 8 equal quarterly installments beginning January 3, 2027.

Remarks:

Exhibit 24: Power of Attorney

	/s/ Ryan J. Selhorn as attorney-in-fact for Greg Pyszczymuka	10/07/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did AYTU insider Greg Pyszczymuka receive?

He received a grant of 12,500 restricted common shares that vest over time, bringing his holdings to 36,102 shares.

At what price were the restricted shares granted to the AYTU CCO?

The restricted shares were granted at a price of $0, indicating a compensatory grant rather than a purchase.

When do the restricted shares vest for the AYTU grant?

One‑third vests on 10/03/2026, with the remaining shares vesting in eight equal quarterly installments beginning 01/03/2027.

How many AYTU shares does the reporting person own after the grant?

The reporting person beneficially owns 36,102 shares following the reported transaction.

Is this transaction a purchase or a compensatory award?

This is a compensatory restricted stock grant (non‑derivative) issued at $0.